Testing dapagliflozin for heart failure on dialysis
Treatments studied
Part of Heart & circulation clinical trials.
This trial tests whether adding dapagliflozin (a medication that helps protect the heart and kidneys) helps people with heart failure who are also on peritoneal dialysis. It may offer extra support for your heart and kidney health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have been diagnosed with heart failure (NYHA class I–III).
- You are currently on peritoneal dialysis (a type of home dialysis).
- You have chronic kidney disease (with a kidney function level below 60).
- You have been on a stable dose of a water pill (furosemide or similar) for at least 14 days.
- You have not been hospitalized for heart failure in the past month.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether dapagliflozin can improve kidney and heart-related outcomes in people with severe chronic kidney disease (CKD). You would take the study medicine (or a comparison treatment) and be followed to see how your kidneys and heart do over time.
This study tests whether dapagliflozin (a medicine already approved for other heart conditions) can help protect kidney and heart function in people with very advanced heart failure who are waiting for a heart transplant. If you qualify, you'll help researchers learn if this drug offers extra benefits beyond standard care.
This trial studies whether dapagliflozin (a heart-failure medicine) can improve anemia in people with heart failure. It may help explain why some patients feel better and how anemia changes when this medicine is used.
This study tests whether a medicine called an SGLT2 inhibitor (which lowers blood sugar and helps the kidneys) can improve outcomes for people with acute heart failure and kidney problems. Participation involves taking the study drug or a placebo for a short time.
This trial tests whether a diabetes drug called dapagliflozin can help people on peritoneal dialysis keep their remaining kidney function longer. It is for patients who started dialysis recently and still make urine.
This trial tests if dapagliflozin helps reduce fat around the heart in people with a type of heart failure where the heart pumps normally but is stiff. It might improve symptoms and overall health.
Hear when a new Heart failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.